IAG to present on Radiomics and Reporter Gene Imaging at RSNA’19
We are pleased to announce that two abstracts from IAG’s expert team were accepted for presentation at Radiology Society of North America (RSNA), 1-7 December 2019, Chicago, USA.
‘Reporter Gene Imaging and Its Potential Role in Drug Development‘, by F Shaikh, MD; E Kurtys, PhD; O A Kubassova, PhD; D Roettger, PhD; T Haywood discussing Reporter Gene Imaging (RGI), which involves imaging of encoding proteins that can be rapidly and sensitively assayed as surrogate markers when fused with regulatory regions of the gene of interest. This abstract presents how RGI can be used in drug development for pharmacodynamic and pharmacokinetic assessment of cellular, gene, oncolytic viral and immunotherapeutic approaches using MRI, PET, SPECT, Ultrasound, Bioluminescence and Fluoroscence. Some of the teaching points include further insight into RGI imaging probes that can be direct, indirect or activable; range from enzymes, protein receptors and cell membrane transporters and how RGI qualitatively and quantitatively assesses cell targeting, transfection, protein expression and intracellular processes.
‘Radiomics in Clinical Trials – The Rationale, Current Practices, and Future Considerations’, by F. Shaikh, MD, PA; D Roettger, PhD; E Kurtys; O A Awan, MD; O A Kubassova, PhD, focused on radiomics, which involves deep quantitative analysis of radiological images for structural and/or functional information. It is a phenomic assessment of disease to understand lesion microstructure, microenvironment and molecular/cellular function. In particular, the abstract presents how in oncology, the radiomics can help accurately classify, stratify and prognosticate tumours based on if, how and when they transform, infiltrate, involute or metastasize. We will be sharing case studies on how to integrate radiomics in an imaging-based clinical trials and how to streamline workflow to handle large datasets, robust platforms to accommodate machine learning calculations, and seamless incorporation of derived insights into outcomes matrix.
These abstracts are examples of our ongoing pursuit of scientific excellence in the field of medical imaging by providing cutting edge imaging techniques and quantitative methodologies for assessment of treatment efficacy and vetting them through scientific process for robustness and reproducibility.
IAG’s team will be attending the meeting to discuss novel strategies in drug development that include advanced imaging biomarkers in the clinical development process.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: wp1.ia-grp.com
Reach out: imaging.experts@ia-grp.com
Follow the Company: Linkedin
About RSNA
The Radiological Society of North America (RSNA) is a non-profit organization with over 54,000 members from 136 countries around the world. It provides high-quality educational resources, including continuing education credits toward physicians’ certification maintenance, host the world’s largest radiology conference and publish two top peer-reviewed journals: Radiology and RadioGraphics. The society is dedicated to building the future of radiology profession, whether that’s through our Research & Education Foundation, which has funded $60 million in grants since its inception, our solutions to support standards development or educational outreach to low-resource nations. https://www.rsna.org/annual-meeting